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Abstract. 
 
The urokinase-type plasminogen activator
receptor (uPAR) is involved in the regulation of cell
motility in a variety of cell types. We show here that ex-
pression of human uPAR in growing murine ﬁbroblasts
leads to a dramatic reorganization of the actin cytoskel-
eton. uPAR expression induces multiple rapidly ad-
vancing protrusions that resemble the leading edge of
migrating cells. The cytoskeletal changes are indepen-
dent of uPA and activation of the RGD-binding activity
of integrins but require uPAR binding to vitronectin
(VN). The actin reorganization is blocked by coexpres-
sion of dominant negative versions of either Rac
(N17Rac) or p130Cas, but not by inhibitors of Cdc42 or
Rho, and is accompanied by a Rac-dependent increase
in cell motility. In addition, a fourfold increase in the
level of activated Rac is induced by uPAR expression.
We conclude that uPAR interacts with VN both to ini-
tiate a p130Cas/Rac-dependent signaling pathway lead-
ing to actin reorganization and increased cell motility
and to act as an adhesion receptor required for these
responses. This mechanism may play a role in uPAR-
mediated regulation of cell motility at sites where VN
and uPAR are co-expressed, such as malignant tumors.
Key words: cell migration • Rho family GTPases •
vitronectin • cytoskeleton • urokinase-type plasmino-
gen activator receptor
 
Introduction
 
Cell migration is involved in many normal physiological
processes such as embryonic development, wound heal-
ing, and mobilization of host defense against infections,
whereas temporal and spatial deregulation of migration
plays a major role in diseases such as cancer and inflam-
mation. The regulation of cell motility is complex and in-
volves numerous intracellular pathways with a dynamic re-
organization of the actin cytoskeleton playing a decisive
part (for reviews see Lauffenburger and Horwitz, 1996;
Mitchison and Cramer, 1996).
The glycosyl phosphatidylinositol–anchored urokinase-
 
type plasminogen activator receptor (uPAR)
 
1
 
 has an impor-
tant role in the regulation of cell motility (for review see
Andreasen et al., 1997). It was initially identified as a cellu-
lar binding site for the serine protease uPA (Stoppelli et al.,
1985; Vassalli et al., 1985), but in addition it binds the extra-
cellular matrix molecule vitronectin (VN) (Wei et al., 1994;
Kanse et al., 1996) and a cleaved form of high molecular
mass kininogen (Colman et al., 1997). The receptor also as-
sociates with integrins (for reviews see Chapman et al.,
1999; Ossowski and Aguirre-Ghiso, 2000), a newly identi-
fied member of the macrophage mannose receptor family
(Behrendt et al., 2000), and intracellularly with the multi-
functional cation-independent mannose 6-phosphate recep-
tor (Nykjær et al., 1998). uPAR is extensively glycosylated
and composed of three homologous domains (D1, D2, and
D3) (for review see Behrendt et al., 1995). The binding of
both uPA and VN to uPAR involves direct interaction with
D1 but requires the integrity of the full-length receptor
(Ploug et al., 1994; Behrendt et al., 1996; Kanse et al., 1996;
Høyer-Hansen et al., 1997; Sidenius and Blasi, 2000). The li-
gation of uPAR with uPA enhances uPAR affinity for VN;
however, it is not essential for uPAR–VN interaction (Wei
et al., 1994; Kanse et al., 1996; Høyer-Hansen et al., 1997;
Aguirre Ghiso et al., 1999; Carriero et al., 1999).
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uPAR appears to have several roles in cell motility regu-
lation. It serves to localize proteolytic activity on the sur-
face during invasive processes (for review see Mignatti
and Rifkin, 1993), but it can also function as a signaling re-
ceptor since proteolytically inactive uPA variants induce
both chemotaxis/chemokinesis and a wide range of signal
transduction effects (for reviews see Blasi, 1999; Ko-
shelnick et al., 1999; Ossowski and Aguirre-Ghiso, 2000).
A uPA-independent role for the receptor in the migration
of leukocytes and epithelial cells has also been reported
(Gyetko et al., 1994, 2000; Nguyen et al., 1999; Wilson and
Gibson, 2000).
Though the activation of the 
 
src
 
-type kinase p56/
p59
 
hck
 
, PKC, extracellular signal–regulated kinase (ERK),
and phosphatidylinositol 3-kinase (PI3K) (Busso et al.,
1994; Resnati et al., 1996; Fibbi et al., 1998; Nguyen et
al., 1999; Kusch et al., 2000) have each been linked to a
uPA-induced increase of cell motility in different cell
types, the mechanism by which uPAR transduces signals
to regulate cell migration remains largely uncharacter-
ized. uPAR has been coimmunoprecipitated with 
 
a
 
V
 
b
 
5
as well as 
 
b
 
1 or 
 
b
 
2 integrins from a variety of cell lines,
and direct in vitro binding between the integrin 
 
a
 
M
 
b
 
2/
CR3/Mac-1 and uPAR has been shown, raising the possi-
bility that integrins might function as transmembrane
adaptors (Bohuslav et al., 1995; Wei et al., 1996; Xue et
al., 1997; Aguirre Ghiso et al., 1999; Carriero et al., 1999;
Chapman et al., 1999; Preissner et al., 2000). In addition,
uPAR can regulate integrin function by direct associa-
tion with integrin-containing complexes (Simon et al.,
1996; Sitrin et al., 1996; Wei et al., 1996; Aguirre Ghiso
et al., 1999; Carriero et al., 1999; Yebra et al., 1999). An
additional complication to the role of uPAR in cell adhe-
sion and motility is its ability to bind VN. Binding of
multimeric or surface-absorbed forms of VN to uPAR
has been demonstrated both in vitro with purified com-
ponents and in vivo where the uPAR–VN interaction
mediates cellular adhesion of cytokine-stimulated mono-
cytes as well as uPAR-transfected HEK293 and eryth-
roid progenitor cells (Wei et al., 1994; Deng et al., 1996;
Kanse et al., 1996; Preissner et al., 2000; Sidenius and
Blasi, 2000).
The interactions of uPAR with components normally
associated with cytoskeletal structures such as integrins
and extracellular matrix molecules and its colocalization
with integrins and cytoskeletal components such as vincu-
lin at sites of cell–matrix contact (Hebert and Baker, 1988;
Pollanen et al., 1988; Myohanen et al., 1993; Wilcox et al.,
1996; Kindzelskii et al., 1997; Xue et al., 1997) suggest that
its role in cell motility may involve regulation of the actin
cytoskeleton. Supporting this, uPA can induce uPAR-
mediated changes in vascular smooth muscle cell morphol-
ogy via a pertussis toxin and herbimycin A–sensitive path-
way as well as a pathway involving Tyk2 and PI3K (Degryse
et al., 1999; Kusch et al., 2000). In addition, uPAR appears
to be necessary for the induction of 
 
a
 
V
 
b
 
5-dependent actin-
rich protrusions in HT-1080 cells (Carriero et al., 1999).
In the regulation of the actin cytoskeleton, small GTPases
of the Rho family play a pivotal role (for reviews see Van
Aelst and D’Souza-Schorey, 1997; Hall, 1998). The best
characterized members of this family, Rho, Rac, and
Cdc42, regulate the assembly of stress fibers, lamellipodia/
ruffles, and filopodia, respectively (Ridley and Hall, 1992;
Ridley et al., 1992; Kozma et al., 1995; Nobes and Hall,
1995). In cell migration, Rac appears to have a critical role
in regulating protrusive activity at the leading edge of
cells, Cdc42 controls directional cues, and Rho appears to
regulate aspects of cell adhesion and contraction (Allen et
al., 1998; Nobes and Hall, 1999).
We have investigated the role of uPAR in actin cyto-
skeleton and cell motility regulation in fibroblasts. We find
that the interaction of uPAR with VN induces protrusions
and increased cell motility and that these effects are de-
pendent on activation of Rac.
 
Materials and Methods
 
Reagents
 
Mouse monoclonal antibodies R2, R3, and R9 against human uPAR were
a gift from Drs. Ebbe Rønne and Gunilla Høyer-Hansen (Finsen Labora-
tory, Copenhagen, Denmark). Mouse monoclonal anti-VN 13H1 and hu-
man VN purified as described previously (Preissner et al., 1985) were gifts
from Dr. Klaus Preissner (Justus Liebig University, Giessen, Germany).
Rabbit polyclonal anti–human IgG (Nykjær et al., 1998) was a gift from
Dr. Anders Nykjær (University of Aarhus, Aarhus, Denmark). Human
uPA and diisopropylfluorophosphate (DFP)-treated human uPA were
gifts from Dr. Peter Andreasen (University of Aarhus, Denmark). Mouse
monoclonal 9E10 against the myc epitope was produced in house, biotin-
conjugated 9E10 was from Cymbus Biotechnology, mouse monoclonal
anti-Rac (clone 23A8) and rabbit polyclonal anti–glutathione 
 
S
 
-trans-
ferase (GST) were from Upstate Biotechnology, mouse monoclonals
antivinculin (VIN-11-5), antiphosphotyrosine (PT 66), as well as VN,
fibronectin (FN), the phosphatidylinositol-specific PLC (PIPLC), rho-
damine-conjugated phalloidin, and pertussis toxin were from Sigma-
Aldrich. Mouse monoclonal antipaxillin was from Zymed Laboratories.
Hamster monoclonal anti–mouse 
 
b
 
3 (2C9.G2) and mouse monoclonal
anti–human CD11b (ICRF44) were from BD PharMingen. FITC-conju-
gated goat anti–rabbit, FITC-conjugated goat anti–mouse, and TRITC-
conjugated donkey anti–rabbit antibodies were purchased from Jackson
ImmunoResearch Laboratories. C3 transferase protein and GST–PAK–
CRIB fusion protein were produced as described previously (Sander et
al., 1998; Nobes and Hall, 1999). The peptides GRGDdSP and GPen-
GRGDSPCA were from GIBCO BRL. Herbimycin A, bisindolylmaleim-
ide I, Gö 6983, and U71322 were from Calbiochem.
 
Cell Culture
 
Swiss 3T3 and COS-7 cells were grown and passaged in DME containing
10% FCS and penicillin/streptomycin (100 IU/ml and 100 
 
m
 
g/ml). For cul-
ture of NIH 3T3 cells, FCS was replaced by donor calf serum. Swiss 3T3
cells were used for passages 7–14 and NIH 3T3 cells for passages 11–20.
For passaging, cells were washed twice in sterile PBS, trypsinized with 0.5
ml trypsin (2.5 mg/ml) (GIBCO BRL) for 1 min, and resuspended in
DME plus 10% FCS.
 
Immunocytochemistry
 
Cells on coverslips were permeabilized by incubation in 0.2% Triton
X-100 in PBS for 5 min, then incubated for 10 min in sodium borohydride
(0.5 mg/ml). For double immunofluorescence staining, cells were incu-
bated with the primary antibody (5–10 
 
m
 
g/ml) in PBS for 30 min, followed
by incubation with the secondary FITC-conjugated antibody (1:200) and
rhodamine-conjugated phalloidin (0.1 
 
m
 
g/ml) in PBS for 30 min. Cover-
slips were exposed to the above solutions by placing them upside down in
drops of 50 
 
m
 
l of liquid. Between incubations, cells were washed five times
by immersion in PBS. For three-way immunofluorescence detection of
uPAR expression, myc-tagged construct expression, and actin changes,
coverslips were first incubated in a solution of rabbit anti–human uPAR
IgG and biotin-conjugated mouse monoclonal anti-myc (9E10) antibod-
ies, followed by a solution of FITC–goat anti–rabbit antibody, Alexa-
conjugated streptavidin (Molecular Probes), and rhodamine-conjugated
phalloidin. Coverslips were mounted, analyzed, and photographed as de-
scribed previously (Nobes and Hall, 1999).
 
Cell Morphology Assays
 
For cell morphology assays with growing Swiss 3T3 cells in the presence of
10% FCS, cells were trypsinized as described above and plated on 13-mm 
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glass coverslips at a density of 3 
 
3
 
 10
 
3
 
 cells/coverslip and used for injection
16 h later. For assays under serum-free conditions, coverslips were coated
with VN (10 
 
m
 
g/ml) or FN (50 
 
m
 
g/ml) for 1 h at 37
 
8
 
C, washed once in PBS
and once in serum-free medium, and overlaid with 800 
 
m
 
l serum-free me-
dium. Cells were then trypsinized as described above, pelleted by centrifu-
gation at 1,000 rpm for 2 min, washed two times in serum-free medium, and
seeded on coverslips at a density of 6 
 
3
 
 10
 
3
 
 cells/coverslip. 2 h later, cells
were used for injection. For assays with quiescent serum-starved Swiss 3T3
cells, cells were plated at 2 
 
3
 
 10
 
5
 
 in 60-mm dishes in DME plus 5% FCS and
antibiotics. 8 d later, the overlaying medium was collected, cells were
trypsinized as above, the trypsin was inhibited by addition of 10 ml serum-
free medium containing 0.5 mg/ml soybean trypsin inhibitor, and cells were
pelleted by centrifugation at 1,000 rpm for 2 min and resuspended in serum-
free medium. 25–70 
 
m
 
l of the cell suspension was added to coverslips coated
with VN or FN as described above, and collected medium was added at a
1:40 dilution. Cells were used for injection 40 h later. Cells were injected
with the expression plasmids pRc/CMV–uPAR, pRK5–myc-V12Rac,
pRK5–myc-N17Cdc42, pRK5–myc-N17Rac, pRK5–myc-Wiskott-Aldrich
syndrome protein (WASP)(201–321), pRK5-CD11b, pRK5-CD18 (Caron
and Hall, 1998), pSSR
 
a
 
-p130Cas
 
D
 
SD, pEBG–GST-p130Cas
 
D
 
SD (Mayer et
al., 1995; Cho and Klemke, 2000), or C3 transferase protein as indicated in
the text and figure legends. 4 or 8 h after injection, coverslips were washed
once in PBS, fixed for 9 min in 4% paraformaldehyde at room temperature,
and washed again in 2
 
3 
 
PBS. For some experiments, DFP–uPA, VN, anti-
bodies, or RGD peptides were added to the coverslips as indicated in the
figure legends. For some experiments, cells were pretreated with inhibitors
for the indicated concentrations and times: pertussis toxin (100 ng/ml, 16 h),
bisindolylmaleimide I or Gö 6983 (1 
 
m
 
M, 30 min), herbimycin A (1 
 
m
 
M,
16 h), PD98059 (60 
 
m
 
M, 30 min), or wortmannin (100 
 
m
 
M, 30 min).
 
Determination of Rac Activity
 
NIH 3T3 cells at 50% confluency were trypsinized, washed twice in Hebs
buffer (20 mM Hepes, 137 mM NaCl, 5 m KCl, 0.7 mM Na
 
2
 
HPO
 
4
 
, 6 mM
D-glucose, pH 7.5), resuspended in 1 ml Hebs with 20 
 
m
 
g of the desired
plasmid DNA, and electroporated with a single pulse at 500 
 
m
 
F, 274 V us-
ing a Bio-Rad Laboratories Gene Pulser. 4, 8, or 16 h after transfection,
cells were washed twice in ice-cold TBS (50 mM Tris, 150 mM Nacl, pH
7.5), transferred to 4
 
8
 
C, and lysed in Ripa buffer (TBS plus 1% Triton
X-100, 0.5% sodium deoxycholate, 0.l% SDS, 10 mM MgCl
 
2
 
, 0.2 mM
PMSF, 10 
 
m
 
g/ml aprotinin/leupeptin). Lysates were cleared by centrifuga-
tion at 13,000 rpm for 2 min, samples were withdrawn for analysis of total
Rac, and the remaining lysate was incubated for 30 min at 4
 
8
 
C with 20 
 
m
 
g of
a 50% slurry of GST–PAK–CRIB fusion protein on glutathione-coupled
agarose beads. Beads were then washed three times in TBS plus 1% Triton
X-100, 10 mM MgCl
 
2
 
, 0.2 mM PMSF, 10 
 
m
 
g/ml aprotinin/leupeptin. Equal
amounts of protein from total cell lysates and corresponding amounts of the
beads solution were then analyzed for Rac content by SDS-PAGE and im-
munoblotting using mouse monoclonal anti-Rac clone 23A8.
 
Adhesion Assays
 
NIH 3T3 cells were transfected by electroporation with the desired plas-
mids as described above. The green fluorescent protein (GFP) expression
vector pEGFP-C1 (CLONTECH Laboratories, Inc.) was included to al-
low detection of transfected cells. For detachment assays, cells were
seeded directly after electroporation on glass coverslips in DME contain-
ing 10% FCS at a density of 10
 
4
 
 cells/coverslip. After 16 h, cells were
treated with 5 mM EDTA in the same medium for 10 min and shaken gen-
Figure 1. Effect of uPAR expression on cell morphology. (A) Cells in growth medium (DME plus 10% FCS or donor calf serum)
were injected with the expression plasmid pRc/CMV-uPAR (100 mg/ml) or with FITC-dextran for controls. As an additional control,
cells were injected with an empty expression vector, and these cells were identical to FITC-dextran–injected cells (data not shown).
4 h after injection, the cells were fixed, uPAR-expressing cells were identified by double immunofluorescence with a rabbit poly-
clonal anti–human uPAR (Nykjær et al., 1998) followed by FITC goat anti–mouse IgG, and the actin cytoskeleton was visualized
with rhodamine-phalloidin. Typical morphologies of the actin cytoskeleton in uPAR-expressing and control cells in three different
cell lines are shown. (B) Localization of ectopically expressed uPAR. Swiss 3T3 cells injected with pRc/CMV-uPAR were fixed and
stained as described in A. The localization of uPAR and the organization of the actin cytoskeleton are shown. Bars, 10 mm. 
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tly. Cells were then washed in PBS and fixed as described above. For at-
tachment assays, cells were trypsinized 24 h after transfection, resus-
pended in DME with 10% FCS in sterile tubes (no. 2097; Falcon), and
incubated for 2 h at 37
 
8
 
C. Cells were then seeded on glass coverslips cov-
ered with medium containing additions as indicated in the figure legends.
After 60 min, the coverslips were washed and fixed as described above.
For both types of assay, the number of transfected adherent cells was de-
termined by counting the number of GFP-positive cells in five fields at
100
 
3
 
 magnification.
 
Time-lapse Videomicroscopy and Cell Motility
 
For time-lapse videomicroscopy of protrusion dynamics, growing cells on
coverslips prepared as described above were injected with pRc/CMV–
uPAR (100 
 
m
 
g/ml), then placed in DME plus 10% FCS and antibiotics,
and buffered with 5 mM Hepes without sodium bicarbonate. Cells were
allowed to recover for 1 h at 37
 
8
 
C at the atmospheric level of CO
 
2
 
 before
filming. For analysis of cell motility, cells were injected as described above
and allowed to express for 3 h before filming was commenced. Cells were
filmed as described (Nobes and Hall, 1999) at a rate of two frames per 10 s.
Images for publishing were produced by grabbing single frames using
ImageGrabber 1.16 software and further processed in Adobe Photoshop
 
®
 
.
 
Results
 
Effect of uPAR on Cell Morphology and the
Actin Cytoskeleton
 
To analyze the effects of uPAR on the actin cytoskeleton,
an expression vector for human uPAR was microinjected
into murine fibroblasts. Since murine uPA does not bind to
human uPAR (Appella et al., 1987; Estreicher et al., 1989;
Quax et al., 1998), the specific effects of uPAR expression
in the absence and presence of bound uPA could be ana-
lyzed. Surprisingly, uPAR expression by itself induced dra-
matic changes in the organization of the actin cytoskeleton
in Swiss 3T3 cells growing in serum at subconfluent density.
uPAR induced the appearance of multiple extending pro-
trusions in 70–100% of the cells 4 h after injection (Fig. 1
A). The addition of human uPA (0.1–10 nM) had no ob-
servable effect on control or uPAR-expressing cells (data
not shown). Time-course studies revealed that protrusions
appeared 2 h after injection and were present for at least 16 h
after injection. Control cells injected with FITC-dextran
or an empty expression vector exhibited only a few minor
Figure 2. Effect of uPAR on vinculin localization and cell protru-
sion dynamics. (A) Swiss 3T3 cells were injected with pRc/CMV-
uPAR (100 mg/ml) as described in the legend to Fig. 1. Vinculin
localization was visualized by double immunofluorescence with
mouse antivinculin (VIN-11-5) followed by FITC goat anti–mouse
IgG. Representative examples of vinculin distribution in control
and uPAR-expressing cells are shown. (B) Swiss 3T3 cells were in-
jected with pRc/CMV-uPAR (100 mg/ml), allowed to recover for
1 h, and then analyzed by time-lapse videomicroscopy. A total of
15 individual cells were examined exhibiting identical responses.
Images of a representative cell captured at the indicated times are
shown. After time-lapse videomicroscopy, cells were fixed and
stained to confirm uPAR expression. (C) Single protrusion dy-
namics in uPAR-expressing Swiss 3T3 cells. Cells were treated
and analyzed as described in B. The extension of two separate
protrusions within 2 min is indicated by arrowheads. Bars, 10 mm.
Figure 3. Role of uPAR interaction with VN in the induction of
protrusions and uPAR localization. (A) Swiss 3T3 cells were in-
jected with pRc/CMV-uPAR (100 mg/ml) and returned to growth
medium without additions (none) or containing PIPLC (2 U/ml),
mouse monoclonal antibody (Mab) against human uPAR clones
R2, R3, and R9 (30 mg/ml), or mouse monoclonal antibody clone
13H1 (30 mg/ml) against VN as indicated. Cells were fixed and
stained as described above and the number of uPAR-expressing
cells exhibiting clearly identifiable protrusions was determined.
Data are average 6 SD for at least three experiments, each ex-
amining 100 injected cells. (B) uPAR-expressing cells treated
with anti-uPAR R9 or anti-VN 13H1 were fixed, and uPAR lo-
calization was visualized as described in the legend to Fig. 1 A.
Typical examples of uPAR distribution are shown. Bar, 10 mm. 
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protrusions similarly to uninjected cells. The actin reorgani-
zation induced by uPAR expression resembled that found
at the leading edge of migrating cells, with an actin-dense
lamellipodia at the leading edge of the protrusion and few
actin structures in the rest of the protrusions (Fig. 1 A).
uPAR itself was found in clusters partially colocalizing with
the extending protrusions (Fig. 1 B). The observed effects
were not due to cell type specificity since identical effects
were observed in 70–100% of uPAR-expressing murine
NIH 3T3 and african green monkey COS-7 cells (Fig. 1 A).
Since cells also reorganize their adhesion complexes
during migration, we examined the effect of uPAR on
these structures. In control cells, vinculin, a component of
adhesion complexes, localized to classic focal adhesions
(Fig. 2 A). uPAR expression resulted in its relocalization
into smaller punctate complexes that appear at the leading
edge of the extensions. These structures are similar to fo-
cal complexes described previously to be induced by acti-
vated Rac (Nobes and Hall, 1995). Identical changes in the
localization patterns were seen for other adhesion com-
plex components such as paxillin and phosphotyrosine-
containing proteins (data not shown).
Time-lapse videomicroscopy revealed that the protru-
sions were transient and highly motile and as seen in Fig.
2, B and C, the cell outline can completely change within a
period of 15 min and a single protrusion can extend from
the cell periphery within 2 min. These observations sug-
gest that uPAR expression leads to the generation of sig-
nals that alter cell morphology through dynamic regula-
tion of the actin cytoskeleton.
 
Extracellular Interactions of uPAR in
Cytoskeletal Regulation
 
To confirm that the uPAR-induced cytoskeletal changes
and protrusions are due to surface expression of the recep-
tor, PIPLC which removes GPI-linked proteins from the
cell surface was included in the assay. The PIPLC treatment
removed all surface-expressed human uPAR as assessed by
immunofluorescence studies on nonpermeabilized cells
(data not shown). PIPLC treatment blocked the appearance
of protrusions induced by uPAR expression (Fig. 3 A). The
effect of PIPLC was not due to a general effect on protru-
sive activity, since similar protrusions, induced by activated
Rac, were not inhibited by PIPLC treatment (see below).
Further evidence for cell surface activity of uPAR in the in-
duction of protrusions was obtained by examining the effect
of domain-specific monoclonal antibodies against uPAR.
The monoclonal antibody R2, which recognizes an epitope
within domains D2 and D3 (Rønne et al., 1991; Gårdsvoll et
al., 1999), had no effect, whereas the antibodies R3 and R9,
which both recognize the D1 domain, inhibited protrusion
induction by 80–100% (Fig. 3 A). We conclude that uPAR-
induced protrusions require cell surface expression of
uPAR and availability of uPAR D1.
 
Figure 4.
 
Role of RGD-binding integrins in uPAR-induced pro-
trusions and adhesion. (A) Swiss 3T3 cells were injected with
pRc/CMV-uPAR (100 
 
m
 
g/ml) and incubated in growth medium
containing GRGDdSP (RGDd) (1.2 mM), GPenGRGDSPCA
(cRGD) (0.05 mM), or hamster anti–mouse 
 
b
 
3 integrin (clone
2C9.G2) (20 
 
m
 
g/ml) as indicated for 4 h before fixing and stain-
ing. The number of uPAR-expressing cells exhibiting clearly
identifiable protrusions was determined. Data are average 
 
6
 
 SD
for at least three experiments, each examining 100 injected cells.
(B) Swiss 3T3 cells were injected with FITC-dextran or pRC/
CMV-uPAR and treated with cRGD (0.05 mM). The organiza-
tion of the actin cytoskeleton was visualized as described above.
Typical morphologies of uninjected (no inj.) or uPAR-expressing
cells are shown. (C) NIH 3T3 cells transfected with pEGFP-C1
and empty vector or pRC/CMV-uPAR as indicated were sub-
jected to detachment or attachment assays (see Materials and
Methods for details) in the presence of 5 mM EDTA, 0.05 mM
cRGD, and 20 
 
m
 
g/ml anti-uPAR R3 as indicated. Results are ex-
pressed as fraction of adherent cells relative to identically trans-
 
fected cells in the absence of additions. In the absence of addi-
tions, the adhesion efficiencies of uPAR-transfected and control
cells were indistinguishable (data not shown). Data are aver-
age 
 
6 
 
SD for at least two experiments performed in triplicate.
Bars, 10
 
 m
 
m. 
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Role of VN in uPAR-Mediated
Cytoskeletal Rearrangement
 
The uPAR D1 domain has been reported to be essential
for both VN and uPA binding (Ploug et al., 1994; Behrendt
et al., 1996; Høyer-Hansen et al., 1997). Since murine uPA
does not interact with the human receptor, the D1 depen-
dence suggests a role for serum-derived VN in the uPAR-
 
mediated induction of protrusions. The monoclonal anti–
human VN antibody 13H1 has been shown previously to
inhibit binding of human VN to uPAR (Kanse et al., 1996).
Western blotting showed that this antibody also recognizes
bovine VN (data not shown), and the 13H1 antibody to-
tally abolished the uPAR-induced effects (Fig. 3 A). Inter-
estingly, uPAR was localized in a homogenous punctate
pattern throughout the cell when treated with antibodies
against the uPAR D1 domain or VN (Fig. 3 B), indicating
that VN binding affects uPAR localization.
Since uPAR has been described to modulate integrin af-
finity (Chapman et al., 1999; Ossowski and Aguirre-Ghiso,
2000; Preissner et al., 2000), we tested whether de novo
binding of integrins to RGD-containing extracellular ma-
trix proteins was necessary for the uPAR-induced re-
sponse. The peptides GRGDdSP (RGDd) and GPen-
GRGDSPCA (cRGD), known to preferably interfere with
integrin-mediated cell adhesion to FN and VN, respec-
tively (Pierschbacher and Ruoslahti, 1987), were added to
cells before injection of the uPAR expression plasmid. Un-
injected cells were less spread and contained fewer stress
fibers than untreated cells (compare Fig. 4 B and Fig. 1 A),
but the peptides did not inhibit the uPAR-mediated induc-
tion of protrusions, indicating the involvement of an adhe-
sion receptor different from RGD-binding integrins (Fig.
4, A and B). In addition, uPAR-induced protrusions were
not affected by a function-blocking antibody to the inte-
grin 
 
b
 
3 subunit. In contrast, the cRGD and the anti-
 
b
 
3 an-
tibody inhibited Rac-induced protrusions (see below). 
uPAR has been demonstrated to mediate adhesion of
different cell types to VN (Wei et al., 1994; Deng et al.,
1996; Sidenius and Blasi, 2000). To investigate if uPAR
could function as an adhesion receptor in murine fibro-
blasts, NIH 3T3 cells were transfected with the expression
plasmid for human uPAR. The uPAR-transfected NIH
3T3 cells were totally resistant to detachment from serum-
coated coverslips with EDTA, whereas control cells were
easily detached (Fig. 4 C). In addition, uPAR-expressing
cells, but not parental NIH 3T3 cells, were able to attach
to these coverslips in the presence of EDTA or the cRGD
peptide. The attachment of uPAR-transfected cells in the
presence of the cRGD peptide was inhibited by the uPAR
R3 antibody that recognizes the uPAR D1 domain.
To investigate whether VN was sufficient to support
uPAR-induced protrusions under serum-free conditions,
cells in “log phase” were trypsinized, washed extensively
in serum-free medium, and replated on either VN- or FN-
coated coverslips in the absence of serum. 2 h after replat-
ing, the cells were injected with the expression plasmid for
human uPAR. Only uPAR-expressing cells plated on VN
exhibited protrusive structures that were essentially iden-
tical to those seen in the presence of serum, whereas
uPAR expression in cells plated on FN did not produce
protrusions (Fig. 5, A and B). To determine whether solu-
ble VN could induce a cytoskeletal response through its
interaction with uPAR, VN (in the presence of 0.05 mM
cRGD) was added back to control and uPAR-injected
cells plated on FN. A strong induction of lamellipodia was
observed specifically in the uPAR-expressing cells. In con-
trast to the effect of uPAR expression in cells plated on
VN, and thus exposed to a substrate-attached reservoir of
the ligand, the effect of soluble VN was transient with a
strong response after 5 min of treatment but no effect after
Figure 5. Role of extracellular matrix factors in uPAR-induced
protrusions. (A) Growing Swiss 3T3 cells were trypsinized,
washed two times in serum-free medium, and replated in serum-
free medium on coverslips precoated with FN (50 mg/ml) or VN
(10 mg/ml). 2 h after plating, cells were injected with pRc/CMV-
uPAR. After 4 h of expression, cells were fixed, stained, and the
number of uPAR-expressing cells with clearly identifiable protru-
sions/lamellipodia was determined as described above. In some
cases, cells were treated with soluble VN (10 mg/ml) or DFP-uPA
(10 nM) for 5 min in the presence of 0.05 mM cRGD before fixa-
tion. Data are average 6 SD for at least three experiments, each
examining 100 injected cells. (B) Cells plated on FN or VN as indi-
cated were injected with pRC/CMV-uPAR, treated with soluble
VN or DFP-uPA in the presence of 0.05 mM cRGD as indicated,
then fixed and stained as described above. Typical morphologies
of the actin cytoskeleton are shown. Bars, 10 mm. 
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4 h. Short- or long-term treatment with uPA had no ob-
servable effect (Fig. 5, A and B; data not shown).
Taken together, these results suggest that an interaction
between uPAR domain D1 and VN is necessary and suffi-
cient (a) to induce effects on the cytoskeleton in Swiss 3T3
cells and (b) to provide the adhesive force required for
protrusions.
 
Role of Intracellular Signaling Pathways in uPAR 
Induction of Cytoskeletal Changes
 
Previous work has implicated pertussis toxin–inhibitable
Src activation (Fazioli et al., 1997), PKC activation (Busso
et al., 1994; Fibbi et al., 1998; Carriero et al., 1999), or
ERK activation (Nguyen et al., 1999) as involved in
uPAR-mediated effects on the actin cytoskeleton or cell
motility. We tested the effect of pertussis toxin, the Src in-
hibitor herbimycin A, the PKC inhibitors bisindolylmale-
imide I and Gö 6983, or the ERK inhibitors PD98059 and
U0126 on the uPAR-induced changes. Herbimycin A
treatment by itself induced cytoskeletal changes, making
its effect on uPAR-induced changes difficult to interpret.
None of the other treatments had any significant effects
on the uPAR-induced response, although pertussis toxin
did inhibit lysophosphatidic acid–induced ERK activa-
tion, bisindolylmaleimide I and Gö6983 inhibited PMA-
induced ERK activation, and PD98059 and U0126 inhib-
ited platelet-derived growth factor– and EGF-induced
ERK activation (data not shown).
Since Rho GTPases play an instrumental role in actin cy-
toskeleton regulation, we analyzed their role in uPAR in-
duction of protrusions. Coexpression of the dominant nega-
tive N17Rac led to complete inhibition of the induction of
protrusions (Fig. 6 A). In addition, the reorganization of ad-
hesion complexes was totally inhibited (data not shown). In
contrast, coexpression of the dominant negative N17Cdc42
had little effect. To further analyze if Cdc42 activity was re-
quired for protrusion induction, the effect of a fragment
of the Cdc42-specific effector WASP (WASP[201–321]),
which has been demonstrated previously to inhibit Cdc42-
induced responses (Nobes and Hall, 1999), was also exam-
ined. WASP(201–321) had no significant effect on the
induction of protrusions, even though it fully inhibited
morphological changes induced by an activated mutant of
Cdc42 (data not shown). Coinjection of recombinant C3
transferase protein to inhibit Rho activity had no effect on
the ability of uPAR to induce protrusions, although it did
inhibit stress fiber induction by activated Rho.
PI3K is necessary for growth factor–mediated activation
of Rac (Hawkins et al., 1995; Nobes et al., 1995), and Tyk2
and PI3K activation have recently been implicated in
uPAR-mediated regulation of the actin cytoskeleton and
 
Figure 6.
 
Role of Rho GTPases in uPAR-induced protrusions.
(A) Swiss 3T3 cells in growth medium were coinjected with
pRC/CMV-uPAR (100 
 
m
 
g/ml) and the expression plasmids
pRK5–myc-N17Rac (20 
 
m
 
g/ml), pRK5–myc-N17cdc42 (100 
 
m
 
g/
ml), or pRK5–myc-WASP(201–321) (40 
 
m
 
g/ml), or with 30 
 
m
 
g/
ml of recombinant C3 transferase protein as indicated. After 4 h
of expression, cells were fixed. uPAR expression was determined
as described above. Expression of inhibitor constructs was veri-
fied by immunofluorescence staining with biotin-conjugated
mouse anti-myc (clone 9E10) followed by Alexa-conjugated
streptavidin. Data are average 
 
6
 
 SD for at least three experi-
ments, each examining 100 injected cells. (B) Subconfluent quies-
cent Swiss 3T3 cells plated on FN or VN were injected with pRC/
CMV-uPAR (100 
 
m
 
g/ml) or coinjected with pRc/CMV-uPAR (100
 
m
 
g/ml) and pRK5–myc-N17Rac (25 
 
m
 
g/ml) or pRK5–myc-
WASP(201–321) (40 
 
m
 
g/ml) as indicated. After 3–8 h of expression,
 
cells were fixed and stained as described above. The number of
uPAR- or coexpressing cells with clearly identifiable lamellipodia
was determined. Data are average 
 
6
 
 SD for at least three experi-
ments, each examining 100 injected cells. (C) Typical morpholo-
gies of quiescent, subconfluent Swiss 3T3 cells injected with
expression plasmids as described in B. The morphology of the
actin cytoskeleton as visualized by staining with rhodamine-
phalloidin is shown. Typical lamellipodia are indicated by ar-
rowheads. Bars, 10
 
 m
 
m. 
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cell motility (Kusch et al., 2000). Therefore, we have tested
the effect of the PI3K inhibitor wortmannin on the induc-
tion of protrusions by uPAR. The inhibitor was shown to
be active in inhibition of platelet-derived growth factor–
induced ruffles in quiescent Swiss 3T3 cells, but it had no
observable effect on the uPAR-induced protrusions (data
not shown). We conclude that uPAR-induced protrusions
are dependent on Rac but not on Cdc42 or Rho.
 
Effect of uPAR on Rac Activity
 
Activation of Rac in quiescent serum-starved Swiss 3T3
cells leads to the formation of lamellipodia and ruffles at the
cell periphery (Ridley et al., 1992). To determine whether
the interaction of VN with uPAR leads to Rac activation,
quiescent serum-starved Swiss 3T3 cells were plated on FN
or VN and injected with the uPAR expression plasmid.
uPAR-expressing cells plated on VN exhibited a combina-
tion of patches of lamellipodia and small spikes at the cir-
cumference of the cell, whereas uPAR-expressing cells on
FN were devoid of these actin structures (Fig. 6, B and C).
Time-lapse videomicroscopy revealed that the lamellipodia
were actively extending structures, whereas the appearing
spikes were due to a small retraction of the cell cortex (data
not shown). The lamellipodia were dependent on activation
of Rac since they were abolished by coexpression of
N17Rac (Fig. 6, B and C). In contrast, no significant reduc-
tion in lamellipodia was caused by WASP(201–321).
To investigate whether Rac activation could also be de-
tected in growing cells where a strong protrusive activity
was induced by uPAR, the level of GTP-bound Rac was
determined. Growing NIH 3T3 cells were mock-trans-
fected, transfected with uPAR, or cotransfected with
uPAR and wild-type Rac. Activated Rac was precipitated
from cell lysates by the Rac-binding domain of p21-acti-
vated kinase (PAK) fused to GST (Sander et al., 1998). As
seen in Fig. 7 A, an increase in the activity of both endoge-
nous Rac and cotransfected wild-type Rac could be de-
tected in response to uPAR. In cells transfected with wild-
type Rac, uPAR expression induced a fourfold activation
 
of Rac when lysates were analyzed 16 h after transfection
(Fig. 7 B). Assays performed 4, 8, and 16 h after transfec-
tion yielded similar results. We conclude that uPAR in-
duces Rac activation.
To initiate an investigation into the mechanism by which
uPAR activates Rac, we have focused on the possibility
that an integrin might function as a transmembrane adap-
tor for uPAR signaling. The docking protein p130Cas is
phosphorylated upon integrin activation and has been
proposed to participate in Rac activation (for review
see O’Neill et al., 2000). We therefore tested the effect
of a dominant negative version of p130Cas (p130Cas-
 
D
 
SD) on uPAR-induced protrusions. Coexpression of p130Cas-
 
D
 
SD, which lacks the substrate domain for phosphoryla-
tion, strongly inhibited the uPAR-induced effect (Fig. 8
A), suggesting that it plays a role in the pathway leading to
cytoskeletal changes.
The integrin Mac-1 has been shown to bind to uPAR
(Wei et al., 1996; Simon et al., 2000), but it does not signal
downstream to Rac (Caron and Hall, 1998). To test
whether Mac-1 could inhibit uPAR signaling to Rac, the
effect of coexpression of Mac-1 with uPAR was examined.
As seen in Fig. 8 A, Mac-1 strongly inhibited the uPAR-
induced protrusions, whereas it did not affect the ability of
uPAR to mediate adhesion to VN (Fig. 8 B). This suggests
that it could block the interaction of uPAR with a mem-
brane protein required for signaling.
 
Effect of Rac on Cell Morphology
 
We have found that expression of activated Rac in grow-
ing Swiss 3T3 cells also leads to the induction of protru-
sions (Fig. 9) similar to those induced by uPAR (although
they have a less prominent actin meshwork at the leading
edge and the cell body is almost totally devoid of stress fi-
bers). Due to the morphological similarities between
uPAR- and Rac-induced protrusions, we investigated
whether they shared other characteristics. Rac-induced
protrusions were not inhibited by p130Cas
 
D
 
SD or Mac-1
coexpression, indicating that these inhibitors function up-
Figure 7. Effect of uPAR expression on Rac activity in growing NIH 3T3 cells. (A) NIH 3T3 cells were transfected by electroporation
with pRC/CMV-uPAR and/or pRK5–myc-wtRac as indicated. PRK5-myc transfection was used as a control. The levels of total cellular
Rac and GST–PAK–CRIB precipitated active Rac were determined by SDS-PAGE on 15% gels followed by immunoblotting for Rac.
Results shown for endogenous Rac activation are for cells lysed 4 h after transfection. Results shown for cotransfected wtRac activation
are for cells lysed 16 h after transfection. (B) The level of activated Rac from cells lysed 16 h after transfection with pRK5–myc-wtRac or
pRK5–myc-wtRac and pRC/CMV-uPAR was quantified by density scanning using NIH Image software. The ratio of activated to total
Rac was determined and results are expressed relative to the Rac activity in cells transfected with pRK5–myc-wtRac. Results are mean 6
SD from three independent experiments. 
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stream of Rac (data not shown). In addition, Rac-induced
protrusions were not sensitive to PIPLC treatment, but
they were inhibited by treatment with the cyclic RGD
peptide GPenSPRGDCA or by a function-blocking anti-
body to the integrin 
 
a
 
Vb3 (Fig. 9). We conclude that in
contrast to the uPAR-induced protrusions, where uPAR
activates Rac and also acts as a direct adhesion receptor,
the Rac-induced protrusions are dependent on aVb3
binding to the extracellular matrix.
Effect of uPAR Expression on Cell Motility
The effect of uPAR on cell motility was analyzed by time-
lapse videomicroscopy. Cells were injected with expres-
sion plasmids as indicated in the legend to Fig. 10. 3 h after
injection, cells were filmed for 3 h, fixed, and protein ex-
pression in the observed cells was confirmed by immuno-
fluorescence. For quantification of motility, the position of
the center of the cell nucleus was manually tracked at
2-min intervals throughout the 3-h period and the distance
of its movement was calculated. uPAR expression induced
a threefold increase in cell migration which was com-
pletely inhibited by coexpression of N17Rac. Examination
of the migration paths revealed that both basal and uPAR-
induced cell migration occurred in a nondirectional “ran-
dom” manner with cells changing their course several
times during the assay (data not shown). We conclude that
the cytoskeletal changes induced by uPAR-mediated Rac
activation are associated with an increase in cell motility.
Discussion
Many studies have implicated uPAR as an important regu-
lator of cell motility (Andreasen et al., 1997). Its effects ex-
tend beyond the localization of proteolytically active uPA
at the cell surface to encompass both the induction of sig-
naling events after ligation with proteolytically inactive
uPA variants and a poorly characterized uPA-indepen-
dent role (Gyetko et al., 1994; Blasi, 1999; Chapman et al.,
1999; Koshelnick et al., 1999; Gyetko et al., 2000; Ossowski
and Aguirre-Ghiso, 2000; Preissner et al., 2000; Wilson
Figure 8. Effect of p130CasDSD and Mac-1 on uPAR-induced
protrusions. (A) Swiss 3T3 cells in growth medium were coinjected
with pRC/CMV-uPAR (100 mg/ml) and either one of the expres-
sion plasmids pSSRa-p130CasDSD/pEBG-GST-p130CasDSD or
both of the expression plasmids pRK5-CD11b and pRK5-CD18
(a- and b chain of Mac-1). After 4 h of expression, cells were
fixed, stained, and the number of uPAR-expressing cells with
clearly identifiable protrusions was determined as described
above. Expression of inhibitor constructs was verified by immu-
nofluorescence staining using anti-GST (rabbit polyclonal) or
anti-CD11b (clone ICRF 44) as primary antibodies. Expression
of untagged and GST-tagged p130CasDSD gave identical results
and the data were averaged for presentation. Data are average 6
SD for at least three experiments, each examining 100 injected
cells. (B) NIH 3T3 cells transfected with pEGFP-C1 and empty
vector or pRC/CMV-uPAR and/or pRK5-CD11b and pRK5-
CD18 as indicated were subjected to detachment assays (see
Materials and Methods for details) in the presence of 5 mM
EDTA. Results are expressed as the fraction of adherent cells
relative to the number uPAR-transfected adherent cells under
these conditions. Results are mean 6 SD of three experiments
each performed in triplicate.
Figure 9. Effect of V12Rac expression in growing Swiss 3T3 cells.
Swiss 3T3 cells in growth medium were injected with pRK5–myc-
V12Rac (100 mg/ml). Cells were then incubated in the absence or
presence of GRGDdSP (RGDd) (1.2 mM), GPenGRGDSPCA
(cRGD) (0.05 mM), or hamster anti–mouse b3 integrin (clone
2C9.G2) (20 mg/ml) as indicated for 4 h before fixing and staining.
Rac-expressing cells were identified with mouse anti-myc (clone
9E10) followed by FITC goat anti–mouse antibodies, and the
number of cells expressing clearly identifiable protrusions was
determined. Data are average 6 SD for at least three experi-
ments, each examining 100 injected cells. The inset shows the typ-
ical morphology of the actin cytoskeleton in a V12Rac-expressing
cell. Bar, 10 mm.The Journal of Cell Biology, Volume 152, 2001 1154
and Gibson, 2000). Here we show that uPAR expression
has major effects on the actin cytoskeleton leading to the
induction of membrane protrusive activity and increased
cell motility. Since murine uPA, produced by the fibro-
blasts used here, is unable to bind the expressed human
uPAR (Appella et al., 1987; Estreicher et al., 1989; Quax
et al., 1998), it appears that these effects are uPA indepen-
dent. However, inhibition of uPAR binding to VN does
block the uPAR-induced effects on the actin cytoskeleton
and the addition of VN, but not uPA, to cells under serum-
free conditions induces cytoskeletal changes. Further-
more, the uPAR-induced effects are independent of inte-
grin binding to VN. We conclude that interaction of uPAR
with VN is the extracellular event causing the observed ef-
fects on the actin cytoskeleton.
Intracellularly, we find that inhibition of pathways re-
ported previously to be involved in uPA-induced mor-
phology changes or cell motility such as activation of per-
tussis toxin–sensitive G proteins, PKC, ERK, or PI3K
(Busso et al., 1994; Resnati et al., 1996; Fazioli et al., 1997;
Carriero et al., 1999; Degryse et al., 1999; Nguyen et al.,
1999; Kusch et al., 2000), has no effect on uPAR-induced
cytoskeletal changes in Swiss 3T3 cells. In contrast, uPAR-
induced actin reorganization and cell motility are com-
pletely inhibited by inhibition of the small GTPase Rac.
Since uPAR expression also leads to Rac activation in qui-
escent and growing cells, we conclude that activation of
Rac is a key event in the signaling cascade by which
uPAR–VN interaction induces cytoskeletal rearrange-
ment and increased cell motility.
Constitutively activated Rac induces morphological
changes similar to those of uPAR. Intriguingly, both
uPAR and Rac expression have very different effects de-
pending on whether the cells are growing in serum or are
quiescent and serum-starved. Both uPAR and Rac induce
lamellipodia in quiescent Swiss 3T3 cells (Ridley et al.,
1992; Fig. 7), but they give rise to advancing protrusions in
growing Swiss 3T3 cells (Figs. 1 and 10). In uPAR-express-
ing cells, protrusions are inhibited by N17Rac, suggesting
that Rac controls not only lamellipodia formation at the
leading edge but also an activity responsible for mem-
brane protrusion. We find that quiescent cells require pre-
treatment with serum for z12–18 h before uPAR or Rac
expression can induce protrusions (data not shown). A
similar dependence on serum or lysophosphatidic acid has
been reported for the induction of cell surface protrusions
and invasion by Cdc42 or Rac expression in T lymphoma
cells (Stam et al., 1998). Those authors found that the ef-
fects were coupled to a requirement for Rho and PLC ac-
tivity. Although we could not test the effect of the PLC in-
hibitor U73122 due to a toxic effect on subconfluent Swiss
3T3 cells, we found no requirement for Rho in the induc-
tion of protrusions. This indicates that in different cell
types Rac can cooperate with different signaling pathways
to induce membrane protrusive activity.
We also noted some important differences between Rac-
and uPAR-induced protrusions. Extracellularly, the Rac-
induced response is dependent on an integrin, in this case
avb3, similarly to the previously reported requirement for
a4b1 and a5b1 in Rac-induced T lymphocyte spreading on
FN (D’Souza-Schorey et al., 1998). In contrast, the uPAR-
induced cytoskeletal changes as well as uPAR-mediated
adhesion occur in the presence of antagonists of RGD-
binding integrins. Therefore, it appears that uPAR func-
tions both as a mediator of signaling to the cytoskeleton
and as an adhesion receptor through its interaction with
VN. Such a dual function is well known for other adhesion
receptors such as integrins (Giancotti and Ruoslahti,
1999). Intracellularly, the uPAR-induced response is in-
hibited by p130CasDSD but Rac-induced effects are not,
suggesting that p130Cas participates in the uPAR-initiated
pathway leading to Rac activation. Considering the nature
of the intracellular pathway downstream of Rac, it is inter-
esting to note that expression of a kinase-dead mutant of
the Rac effector PAK1 leads to cell shape changes and mo-
tility patterns in NIH 3T3 cells (Sells et al., 1997, 1999) that
are similar to those we observe after uPAR expression in
these cells. Therefore, it is likely that PAK could play a
role in uPAR-initiated signaling to the cytoskeleton that is
independent of its kinase activity.
How does the uPAR–VN complex induce signaling to
the cytoskeleton? VN-dependent clustering of uPAR in
HT 1080 cells has been reported previously (Ciambrone
and McKeown-Longo, 1992), and we have observed that
inhibition of the uPAR–VN interaction, by monoclonal
antibodies or by plating the cells on FN, resulted in a
change in uPAR distribution from large clusters into
smaller punctate structures. Since addition of uPA or clus-
tering of uPAR by antibodies has been reported to induce
several different signaling events (Resnati et al., 1996; Ko-
shelnick et al., 1997; Sitrin et al., 1999), it is possible that
VN could induce signaling through uPAR clustering.
VN is also known to promote colocalization of VN-
binding integrins with uPAR (Xue et al., 1997), and uPAR
has been shown to modulate integrin affinity by a mecha-
nism that might involve direct interaction (Simon et al.,
1996; Sitrin et al., 1996; Wei et al., 1996; Aguirre Ghiso et
al., 1999). The inability of RGD peptides to block the
uPAR-induced response and the fact that uPAR does not
affect adhesion complexes in the presence of N17Rac ar-
Figure 10. Effect of uPAR expression on cell motility. Swiss 3T3
cells in growth medium were injected with pRc/CMV-uPAR (100
mg/ml) and/or pRK5–myc-N17Rac (20 mg/ml), and the average
distance migrated in 3 h was calculated. The effects of uPAR ex-
pression and the effect of N17Rac expression on the uPAR-
induced increase in migration were found to be statistically sig-
nificant by Student’s t test (P , 0.0001). Results are mean 6 SD
from examination of at least 12 individual cells.Kjøller and Hall VN–uPAR Interaction Induces Rac Activation 1155
gue against a direct activation or inactivation of the ma-
trix-binding function of integrins as the cause for the cy-
toskeletal rearrangements shown here. However, it is
possible that one or more integrins could function as trans-
membrane adaptors to propagate a uPAR-induced signal.
The ability of p130CasDSD and Mac-1 to inhibit the induc-
tion of protrusions is consistent with this model. Blasi and
coworkers have shown that exposure of a peptide se-
quence corresponding to amino acids 84–95 (between do-
mains D1 and D2) of uPAR can induce chemotaxis as well
as cytoskeletal changes in monocytic and smooth muscle
cells (Resnati et al., 1996; Degryse et al., 1999), leading to
the suggestion that this sequence might interact with a
transmembrane adaptor. It is possible that uPAR binding
to VN induces a conformational change that either di-
rectly exposes that sequence or makes the region between
uPAR domains D1 and D2 accessible to protease cleavage
and subsequent exposure. The identification of the molec-
ular mechanism propagating VN–uPAR-induced signaling
across the membrane to the cytoskeleton is an important
task for the future.
Previously, the interaction of uPAR with VN has been
suggested to play both positive and negative roles in cell
motility regulation. In some cases, increased uPAR-medi-
ated adhesion to VN induced by uPA was found to inhibit
cell migration on VN (Stahl and Mueller, 1997; Waltz et
al., 1997). However, uPAR expression also induces hapto-
tactic migration of HEK293 or MCF-7 cells onto VN- or
serum-coated surfaces in a uPA-independent manner (Wei
et al., 1996; Nguyen et al., 1999). In addition, endogenous
uPAR is required for uPA-independent monocyte chemo-
taxis, neutrophil recruitment, and epithelial cell wound
healing (Gyetko et al., 1994, 2000; Wilson and Gibson,
2000). It is tempting to speculate that some or all of these
effects might involve activation of an intracellular pathway
similar to the one we describe here. In line with this sug-
gestion, the uPAR-induced effects in MCF-7 cells are in-
sensitive to the inhibition of ERK activation similarly to
our observation in fibroblasts, whereas a uPA-induced in-
crease in MCF-7 motility is not (Nguyen et al., 1999).
Overexpression of uPAR has been widely demonstrated
in several types of tumors and is often associated with poor
prognosis (for review see Andreasen et al., 1997). Further-
more, evidence that VN is expressed at relatively high lev-
els in at least some types of cancer, such as hepatocellular
carcinoma and gliomas, is accumulating (Gladson and
Cheresh, 1991; Gladson et al., 1995; Maenpaa et al., 1997;
Kondoh et al., 1999). Since Rac is essential for cellular in-
vasion in several model systems (Michiels et al., 1995;
Keely et al., 1997; Shaw et al., 1997; Stam et al., 1998; Ban-
yard et al., 2000; Cho and Klemke, 2000), this raises the
possibility that uPAR–VN-induced activation of Rac could
play a role in tumor invasion and cancer metastasis. It will
now be important to determine the role of VN–uPAR-
induced Rac activation in a physiological context and to
characterize further the transmembrane proteins and in-
tracellular signaling molecules mediating this activation.
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